Company to offer $1 alternative to cancer pill hiked 5,000%

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

SAN DIEGO — A drugmaker said Thursday it will sell a version of Daraprim for $1 after Turing Pharmaceuticals hiked the price by over 5,000 percent to $750 a pill.

The pill is currently sold by Turing, a company that has been around for 62 years. Its CEO, Martin Shkreli, made headlines in August when he purchased the company and increased the price of Daraprim from $13.50 to $750.

Imprimis Pharmaceuticals said Thursday the company will offer a customizable compounded formulation of the costly drug in the form of an oral capsule.

The company said, “Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as$99.00 for a 100 count bottle, or at a cost of under a dollar per capsule.  Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient.”

Unlike Daraprim, the formulation is not FDA approved, and can only be used prescribed with a physician prescription.